Table 2.
Univariate regression analysis and odds of death based on clinical and laboratory variables.
| OR | 95% CI | p value | |
|---|---|---|---|
| Sex (M vs F) | 0.713 | 0.374–1.360 | 0.305 |
| ECOG PS (>=/2 vs 0–1) | 4.286 | 2.001–9.183 | 0.000 |
| Age (per 1 year increment) | 1.030 | 1.003–1.057 | 0.030 |
| Current or former smoker (vs no smoker) | 0.750 | 0.295–1.906 | 0.545 |
| At least one comorbidity (vs none) | 1.594 | 0.691–3.677 | 0.274 |
| Two or more comorbidities (vs 0–1) | 2.005 | 1.047–3.839 | 0.036 |
| Hypertension | 1.686 | 0.886–3.208 | 0.11 |
| Stage (IV vs I-III) | 1.658 | 0.844–3.257 | 0.142 |
| Treatment setting (curative vs palliative) | 1.705 | 0.878–3.310 | 0.115 |
| Presence of lung metastases (yes vs no) | 1.435 | 0.617–3.338 | 0.402 |
| Active anticancer therapy (yes vs no) | 1.131 | 0.597–2.141 | 0.706 |
| Chemotherapy (yes vs no) | 1.401 | 0.694–2.830 | 0.347 |
| Presence of symptoms (any vs no) | 2.166 | 0.918–5.114 | 0.078 |
| Fever (yes vs no) | 1.516 | 0.759–3.029 | 0.239 |
| Dyspnoea (yes vs no) | 5.956 | 2.959–11.989 | 0.000 |
| Clinical phenotype (>/03 vs 1–2) | 6.006 | 2.793–12.915 | 0.000 |
| Hospitalisation (yes vs no) | 4.290 | 1.573–11.700 | 0.004 |
| Intensive care unit admission (yes vs no) | 9.061 | 1.856–44.236 | 0.006 |
| Lymphopenia | 2.259 | 0.873–5.845 | 0.093 |
| Neutrophil/lymphocyte ratio (>/=7 vs < 7) | 7.669 | 3.097–18.990 | 0.000 |
| Thrombocytopenia (<150.000 vs >/= 150.000) | 2.770 | 1.306–5.876 | 0.008 |
| LDH (>250 vs </=250) | 1.889 | 0.652–5.476 | 0.242 |
| PCR (>50 vs </0 50) | 1.637 | 0.707–3.790 | 0.250 |
CI, confidence interval; OR, odds ratio; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PCR, C-reactive protein. Bold font indicate the variables with statistical significance.